Jazz, Hikma Must Face Bulk Of Xyrem Antitrust Suit

By Bryan Koenig · August 28, 2024, 7:33 PM EDT

Jazz Pharmaceuticals and Hikma Pharmaceuticals appear bound for trial against most solo insurer and class action antitrust claims over alleged efforts to block generic competitors to Jazz's Xyrem narcolepsy drug, under...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

In re Xyrem (Sodium Oxybate) Antitrust Litigation

Case Number

3:20-md-02966

Court

California Northern

Nature of Suit

Anti-Trust

Date Filed

December 16, 2020

Featured Stories

Trio Of BigLaw Mergers Expected To Drive More Deal Talks No Photo Available

Natalie Rodriguez

After months of a relatively steady pace of law firm mergers and acquisitions, the trio of proposed BigLaw tie-ups announced in recent... (more story)

Will Tom Girardi's Age Impact His Sentence? No Photo Available

Craig Clough

Disbarred attorney Tom Girardi's age and mental decline did not help him avoid conviction last month on charges that he stole millions... (more story)

PE-Backed Red Lobster Has Rocky Route To Post-Ch. 11 Profit No Photo Available

Alex Wittenberg

With court approval of its reorganization plan secured, Red Lobster will soon exit bankruptcy with new owners, a 35-year-old chief exe... (more story)